ABVC

ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

ABVC BioPharma, Inc. (ABVC) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.1
EV / EBITDA -4.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 8.6%
Price Return 12M -66.4%
Catalyst Signal 0.00
Market Cap $25.4M
TTM Revenue N/A
Price / Sales N/A
ROE -52.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C+ (2.5) C- (1.9) C+ (2.6) C+ (2.6) C (2.4)
2026-11-10 C+ (2.5) C+ (2.5) C (2.5) C+ (2.7) C+ (2.6) C+ (2.6)
2026-11-03 C+ (2.5) C+ (2.5) C+ (2.5) C (2.5) C+ (2.7) C+ (2.5)
2026-10-27 C+ (2.5) C+ (2.5) C (2.5) C+ (2.5) C+ (2.6) C+ (2.5)
2026-10-20 C+ (2.5) C+ (2.5) C (2.5) C- (1.9) C+ (2.6) C (2.4)
Page 1 of 6